RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
https://doi.org/10.20996/1819-6446-2012-8-2-12-25
Abstract
Aim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease aged under 70 years were involved into the crossover study. Clinical examination included questionnaire survey , blood pressure (BP) measurement, ECG registration, 24-hour ECG and BP monitoring, determination of blood levels of total cholesterol, high density lipoproteins, triglycerides, transaminases, and creatinine, complete blood cell count, including platelets number and hemoglobin level. Besides evaluation of the platelet aggregation by optical aggregometry was performed initially , after one week ASA treatment and after every next 3 week clopidogrel treatment period. Results. RPAR during ASA monotherapy was 56.4±0.3%. There were no significant differences in effects of original and generic clopidogrel on RPAR. Сlopidogrel therapy reduced RPAR more significantly (42.2±0.2%) than ASA monotherapy did (p=0.0003). Authors proposed definition for high level of RPAR during therapy - it is platelet aggregation more than 46%. Data analysis taking into account this criterion showed that a number of patients with high RPAR was 70 and 30% among patients treated with enterosoluble ASA and clopidogrel, respectively. Conclusion. Study results show that a significant number of patients receiving antiplatelet monotherapy does not achieve the target level of RPAR(<46%). These results may be a rationale for combined therapy in patients of this type.
About the Authors
A. A. Lomonosova
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
N. A. Mazur
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
E. A. Zolozova
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
E. V. Sayutina
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
V. V. Chigineva
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
N. V. Shestakova
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
References
1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996;348(9038):1329–1339.
2. Hochholzer W., Trenk D., Bestehorn H.P . et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742–1750.
3. Beigel R., Hod H., Fefer P ., Asher E. et al. Еn of aspirin failure to clinical outcome and to platalet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 2011; 107 (3), 339–342.
4. Price M. J., Angiolillo D.J , Teirstein P .S. et al. A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. Circulation 2011;124(10):1132–7.
5. Brar S.S., Ten Berg J., Marcucci R. et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58(19):1945–1954 .
6. Gurbel P .A., Antonino M.J., Bliden K.P . et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic targetю. Platelets 2008; 19 (8): 595–604.
7. Bonello L., Tantry U.S., Marcucci R. et al. Consensus and future directions on the definition of high on- treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933.
8. Sibbing D., Braun S., Morath T . et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849–56.
9. Breet N.J., van Werkum J.W., Bouman II.J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754–62.
10. Sibbing D., Morath T., Braun S. et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151–59.
11. Geisler T., Zurn Ch., Simonenko R. et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–66.
12. Price M.J., Endemann S., Collapudi R.R. et al. Prognostic significance of post-clopidogrel platelet re- activity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992–1000.
13. Serebruany V., Rao S.Y ., Silva M.A. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events assessment by different. Eur Heart J 2010; 3: 227–35.
Review
For citations:
Lomonosova A.A., Mazur N.A., Zolozova E.A., Sayutina E.V., Chigineva V.V., Shestakova N.V. RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS. Rational Pharmacotherapy in Cardiology. 2012;8(2):168-172. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-2-12-25
Views: 616
Email this article 